Patents Assigned to Genentech
  • Publication number: 20190169667
    Abstract: Provided herein are cell culture media and methods culturing host cells expressing polypeptides to reduce the level of trisulfide bonds in polypeptides produced by the host cells.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 6, 2019
    Applicant: GENENTECH, INC.
    Inventors: Martin GAWLITZEK, Sven MARKERT, Oliver POPP, Masaru Ken SHIRATORI, Thomas TROEBS, Jessica WUU
  • Publication number: 20190169278
    Abstract: The invention provides antibodies having greater avidity for a mixed-topology polyubiquitin than a single-topology polyubiquitin and multispecific anti-polyubiquitin antibodies, and methods of using the same.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 6, 2019
    Applicant: Genentech, Inc.
    Inventors: Vishva Dixit, Marissa Matsumoto, Erick Castellanos
  • Publication number: 20190167681
    Abstract: The invention provides compounds of formula I: and pharmaceutically acceptable salts thereof where R1 is a substituted or unsubstituted phenyl or a fused bicyclic comprising a substituted or unsubstituted phenyl. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Applicant: Genentech, Inc.
    Inventors: Vishal VERMA, Matthew VOLGRAF, Baihua HU
  • Patent number: 10307426
    Abstract: Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: June 4, 2019
    Assignee: Genentech, Inc.
    Inventors: Mark Zak, F. Anthony Romero, Yun-Xing Cheng
  • Patent number: 10308614
    Abstract: The present invention relates to compounds of formula (I): and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: June 4, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor
  • Patent number: 10308944
    Abstract: The present invention relates to polypeptide expression systems and methods of using the same.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: June 4, 2019
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Yonglei Shang
  • Patent number: 10301253
    Abstract: Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 28, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Cote, Martin Duplessis, Victor S. Gehling, Andrew Charles Good, Jean-Christophe Harmange, Yves LeBlanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • Publication number: 20190152970
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 23, 2019
    Applicant: Genentech, Inc.
    Inventors: Sharada LABADIE, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Zhiguo Liu, Tao Wang
  • Publication number: 20190152949
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 23, 2019
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Publication number: 20190144428
    Abstract: The invention is concerned with the compounds of formula I: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Applicant: Genentech, Inc.
    Inventors: Vishal VERMA, Daniel SHORE, Matthew VOLGRAF, Anthony A. ESTRADA, Joseph LYSSIKATOS
  • Publication number: 20190144430
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 16, 2019
    Applicant: Genentech, Inc.
    Inventors: Baihua HU, Vishal VERMA, Matthew VOLGRAF, Anthony ESTRADA, Joseph LYSSIKATOS
  • Publication number: 20190144817
    Abstract: Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided.
    Type: Application
    Filed: October 4, 2018
    Publication date: May 16, 2019
    Applicant: Genentech, Inc.
    Inventors: Natarajan VIJAYASANKARAN, Steven J. MEIER, Sharat VARMA, Yi YANG
  • Patent number: 10287356
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 14, 2019
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • Publication number: 20190135935
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Application
    Filed: January 4, 2019
    Publication date: May 9, 2019
    Applicant: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Publication number: 20190135936
    Abstract: The invention provides anti-Jagged antibodies and methods of using the same.
    Type: Application
    Filed: September 20, 2018
    Publication date: May 9, 2019
    Applicant: Genentech, Inc.
    Inventors: Christian W. Siebel, Yan Wu
  • Patent number: 10278975
    Abstract: Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 7, 2019
    Assignee: GENENTECH, INC.
    Inventors: Aleksandr Kolesnikov, Steven Do
  • Patent number: 10280144
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, James J. Crawford, Sarah M. Bronner, Monique Bodil van Niel, Andrew Cridland, Emanuela Gancia, Christopher Hurley, Jonathan Killen, Stuart Ward
  • Patent number: 10280149
    Abstract: The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: May 7, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Victor Gehling, Vickie Hsiao-Wei Tsui, James Richard Jr. Kiefer, Jun Liang, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Birong Zhang
  • Patent number: 10280228
    Abstract: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Sharon A. Baughman, Steven Shak
  • Patent number: 10280227
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: May 7, 2019
    Assignee: Genentech, Inc.
    Inventors: Michael Adler, Hanns-Christian Mahler, Oliver Boris Stauch